{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T20:47:50Z","timestamp":1774990070735,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Science and Technology Plan Project of Jiangxi Provincial Health Commission","award":["202410952"],"award-info":[{"award-number":["202410952"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Surg Onc"],"DOI":"10.1186\/s12957-025-03877-0","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:47:14Z","timestamp":1749545234000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["PD-1\/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone as the first line treatment for advanced biliary tract cancer: a pooled analysis of KEYNOTE-966 and TOPAZ-1 trails"],"prefix":"10.1186","volume":"23","author":[{"given":"Jiashou","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingjian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenxiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"issue":"1","key":"3877_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349.","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"3877_CR2","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/nrclinonc.2010.130","volume":"7","author":"W Scheithauer","year":"2010","unstructured":"Scheithauer W. Chemotherapy: Gemcitabine alone or plus cisplatin for biliary tract cancer? Nat Rev Clin Oncol. 2010;7(10):554\u20135.","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"3877_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1002\/ags3.12691","volume":"7","author":"T Ioka","year":"2023","unstructured":"Ioka T, Shindo Y, Ueno M, Nagano H. Current progress in perioperative chemotherapy for biliary tract cancer. Ann Gastroenterol Surg. 2023;7(4):565\u201371.","journal-title":"Ann Gastroenterol Surg"},{"issue":"5","key":"3877_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1080\/17474124.2021.1864325","volume":"15","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G. BILCAP trial and adjuvant capecitabine in resectable biliary tract cancer: reflections on a standard of care. Expert Rev Gastroenterol Hepatol. 2021;15(5):483\u20135.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"16","key":"3877_CR5","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-24-0517","volume":"30","author":"SJ Casak","year":"2024","unstructured":"Casak SJ, Kumar V, Song C, Yuan M, Amatya AK, Cheng J, et al. FDA Approval Summary: Durvalumab and Pembrolizumab, Immune Checkpoint Inhibitors for the Treatment of Biliary Tract Cancer. Clin Cancer Res. 2024;30(16):3371\u20137.","journal-title":"Clin Cancer Res"},{"issue":"18","key":"3877_CR6","doi-asserted-by":"publisher","first-page":"10869","DOI":"10.3390\/ijms231810869","volume":"23","author":"G Brandi","year":"2022","unstructured":"Brandi G, Rizzo A. IDH Inhibitors and Immunotherapy for Biliary Tract Cancer: A Marriage of Convenience? Int J Mol Sci. 2022;23(18):10869.","journal-title":"Int J Mol Sci"},{"key":"3877_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2021.100354","volume":"27","author":"A Rizzo","year":"2021","unstructured":"Rizzo A, Brandi G. Neoadjuvant therapy for cholangiocarcinoma: A comprehensive literature review. Cancer Treat Res Commun. 2021;27: 100354.","journal-title":"Cancer Treat Res Commun"},{"issue":"4","key":"3877_CR8","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.1002\/hep.31862","volume":"74","author":"JG Yoon","year":"2021","unstructured":"Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, et al. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1\/Programmed Death-Ligand 1 Blockade Responses. Hepatology. 2021;74(4):1914\u201331.","journal-title":"Hepatology"},{"key":"3877_CR9","doi-asserted-by":"crossref","unstructured":"Macarulla T, Ren Z, Chon HJ, Park JO, Kim JW, Pressiani T, et al. Atezolizumab Plus Chemotherapy With or Without Bevacizumab in Advanced Biliary Tract Cancer: Clinical and Biomarker Data From the Randomized Phase II IMbrave151 Trial. J Clin Oncol. 2025;43(5):545\u201357.","DOI":"10.1200\/JCO.24.00337"},{"issue":"2","key":"3877_CR10","doi-asserted-by":"publisher","first-page":"S230","DOI":"10.1016\/j.annonc.2024.08.056","volume":"35","author":"S Qin","year":"2024","unstructured":"Qin S, Liang T, Gu S, Gou H, Peng C, Pan Y, et al. 47P First-line pembrolizumab (pembro) + gemcitabine and cisplatin (gem\/cis) for advanced biliary tract cancer (BTC) in the China subpopulation from the phase III KEYNOTE-966 study. Ann Oncol. 2024;35(2):S230.","journal-title":"Ann Oncol"},{"issue":"10391","key":"3877_CR11","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","volume":"401","author":"RK Kelley","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, Finn RS, Furuse J, Ren Z, et al. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10391):1853\u201365.","journal-title":"Lancet"},{"issue":"8","key":"3877_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/S2468-1253(24)00095-5","volume":"9","author":"DY Oh","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, Okusaka T, Qin S, Chen LT, et al. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024;9(8):694\u2013704.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"3877_CR13","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/S1470-2045(24)00082-2","volume":"25","author":"HA Burris 3rd","year":"2024","unstructured":"Burris HA 3rd, Okusaka T, Vogel A, Lee MA, Takahashi H, Breder V, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2024;25(5):626\u201335.","journal-title":"Lancet Oncol"},{"issue":"8","key":"3877_CR14","doi-asserted-by":"publisher","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","volume":"1","author":"DY Oh","year":"2022","unstructured":"Oh DY, Ruth He A, Qin S, Chen LT, Okusaka T, Vogel A, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer. NEJM Evid. 2022;1(8):EVIDoa2200015.","journal-title":"NEJM Evid."},{"key":"3877_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejca.2022.09.014","volume":"176","author":"DW Kim","year":"2022","unstructured":"Kim DW, Kim YC, Kovari BP, Chung V, Alese OB, El-Rayes BF, et al. Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer. Eur J Cancer. 2022;176:171\u201380.","journal-title":"Eur J Cancer"},{"issue":"21","key":"3877_CR16","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.3390\/cancers16213689","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Ayasun R, Rizzo A, Guven DC. Prognostic Value of Neutrophil-to-Eosinophil Ratio (NER) in Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024;16(21):3689.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"3877_CR17","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/cancers16101835","volume":"16","author":"TK Sahin","year":"2024","unstructured":"Sahin TK, Rizzo A, Aksoy S, Guven DC. Prognostic Significance of the Royal Marsden Hospital (RMH) Score in Patients with Cancer: A Systematic Review and Meta-Analysis. Cancers (Basel). 2024;16(10):1835.","journal-title":"Cancers (Basel)"},{"issue":"8","key":"3877_CR18","doi-asserted-by":"publisher","first-page":"4608","DOI":"10.1097\/JS9.0000000000001540","volume":"110","author":"S Wang","year":"2024","unstructured":"Wang S, Wang Y, Zhu C, Liu K, Chao J, Zhang N, et al. Conversion surgery intervention versus continued systemic therapy in patients with a response after PD-1\/PD-L1 inhibitor-based combination therapy for initially unresectable biliary tract cancer: a retrospective cohort study. Int J Surg. 2024;110(8):4608\u201316.","journal-title":"Int J Surg"},{"issue":"1","key":"3877_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"key":"3877_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","volume":"343","author":"JP Higgins","year":"2011","unstructured":"Higgins JP, Altman DG, G\u00f8tzsche PC, J\u00fcni P, Moher D, Oxman AD, et al. The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials. BMJ. 2011;343: d5928.","journal-title":"BMJ"},{"issue":"4","key":"3877_CR21","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","volume":"64","author":"GH Guyatt","year":"2011","unstructured":"Guyatt GH, Oxman AD, Sch\u00fcnemann HJ, Tugwell P, Knottnerus A. GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol. 2011;64(4):380\u20132.","journal-title":"J Clin Epidemiol"},{"key":"3877_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114046","volume":"203","author":"D Zhang","year":"2024","unstructured":"Zhang D, Dorman K, Westphalen CB, Haas M, Ormanns S, Neumann J, et al. Unresectable biliary tract cancer: Current and future systemic therapy. Eur J Cancer. 2024;203: 114046.","journal-title":"Eur J Cancer"},{"issue":"8","key":"3877_CR23","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1016\/S2468-1253(24)00118-3","volume":"9","author":"AD Ricci","year":"2024","unstructured":"Ricci AD, Rizzo A, Lotesoriere C. Immunotherapy in biliary tract cancer: are we finally on the right path? Lancet Gastroenterol Hepatol. 2024;9(8):678\u20139.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"3877_CR24","doi-asserted-by":"publisher","first-page":"1109292","DOI":"10.3389\/fimmu.2023.1109292","volume":"14","author":"C Zhu","year":"2023","unstructured":"Zhu C, Xue J, Wang Y, Wang S, Zhang N, Wang Y, et al. Efficacy and safety of lenvatinib combined with PD-1\/PD-L1 inhibitors plus Gemox chemotherapy in advanced biliary tract cancer. Front Immunol. 2023;14:1109292.","journal-title":"Front Immunol"},{"key":"3877_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114199","volume":"208","author":"M Rimini","year":"2024","unstructured":"Rimini M, Fornaro L, Rizzato MD, Antonuzzo L, Rossari F, Satake T, et al. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population. Eur J Cancer. 2024;208: 114199.","journal-title":"Eur J Cancer"},{"issue":"6","key":"3877_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S2468-1253(22)00052-8","volume":"7","author":"C Neuzillet","year":"2022","unstructured":"Neuzillet C. First-line chemotherapy plus immunotherapy in biliary tract cancer. Lancet Gastroenterol Hepatol. 2022;7(6):496\u20137.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"12","key":"3877_CR27","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1007\/s00262-024-03844-w","volume":"73","author":"Y Han","year":"2024","unstructured":"Han Y, Xiao X, Qin T, Yao S, Liu X, Feng Y, et al. Efficacy and safety of perioperative immunotherapy combinations for resectable non-small cell lung cancer: a systematic review and network meta-analysis. Cancer Immunol Immunother. 2024;73(12):262.","journal-title":"Cancer Immunol Immunother"},{"key":"3877_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.115056","volume":"212","author":"A \u00d6zkan","year":"2024","unstructured":"\u00d6zkan A, Kapiteijn E, van den Bos F, Aarts MJB, van den Berkmortel FWPJ, et al. Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry. Eur J Cancer. 2024;212: 115056.","journal-title":"Eur J Cancer"},{"issue":"11","key":"3877_CR29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00262-024-03796-1","volume":"73","author":"Y Lu","year":"2024","unstructured":"Lu Y, Jin Y, Liu F, Wang Z, Zhou W, Zhang Y, et al. Efficacy of durvalumab plus chemotherapy in advanced biliary duct cancer and biomarkers exploration. Cancer Immunol Immunother. 2024;73(11):220.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3877_CR30","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1186\/s12967-020-02437-2","volume":"18","author":"L Wang","year":"2020","unstructured":"Wang L, Zhu H, Zhao Y, Pan Q, Mao A, Zhu W, et al. Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience. J Transl Med. 2020;18(1):273.","journal-title":"J Transl Med"},{"issue":"15\u201316","key":"3877_CR31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1080\/17520363.2024.2385297","volume":"18","author":"Y Lou","year":"2024","unstructured":"Lou Y, Chen Y, Guo K, Li B, Zheng S. Emerging biomarkers for immunotherapy response in biliary tract cancers: a comprehensive review of immune checkpoint inhibitor strategies. Biomark Med. 2024;18(15\u201316):703\u201315.","journal-title":"Biomark Med"},{"issue":"12","key":"3877_CR32","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00262-024-03842-y","volume":"73","author":"P Reimann","year":"2024","unstructured":"Reimann P, Mavroeidi IA, Burghofer J, Taghizadeh H, Webersinke G, Kasper S, et al. Exploring the impact of durvalumab on biliary tract cancer: insights from real-world clinical data. Cancer Immunol Immunother. 2024;73(12):251.","journal-title":"Cancer Immunol Immunother"},{"key":"3877_CR33","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03707-x","author":"J Zhao","year":"2024","unstructured":"Zhao J, Guo H, Wu C, Guo H. Efficacy and safety of camrelizumab combined with chemotherapy in the treatment of advanced biliary malignancy and associations between peripheral blood lymphocyte subsets and clinical outcomes. Clin Transl Oncol. 2024. https:\/\/doi.org\/10.1007\/s12094-024-03707-x.","journal-title":"Clin Transl Oncol"},{"key":"3877_CR34","doi-asserted-by":"publisher","first-page":"1433235","DOI":"10.3389\/fimmu.2024.1433235","volume":"15","author":"C Tang","year":"2024","unstructured":"Tang C, Kong Y, Xu L, Duan C, Fu X, Fang L, et al. Preliminary response to Tislelizumab plus chemotherapy drugs in patient with periampullary carcinoma: a report of one case and a literature review. Front Immunol. 2024;15:1433235.","journal-title":"Front Immunol"},{"issue":"8","key":"3877_CR35","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11864-024-01243-y","volume":"25","author":"S Yue","year":"2024","unstructured":"Yue S, Zhang Y, Zhang W. Recent Advances in Immunotherapy for Advanced Biliary Tract Cancer. Curr Treat Options Oncol. 2024;25(8):1089\u2013111.","journal-title":"Curr Treat Options Oncol"},{"key":"3877_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102751","volume":"127","author":"L Rached","year":"2024","unstructured":"Rached L, Laparra A, Sakkal M, Danlos FX, Barlesi F, Carbonnel F, et al. Toxicity of immunotherapy combinations with chemotherapy across tumor indications: Current knowledge and practical recommendations. Cancer Treat Rev. 2024;127: 102751.","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"3877_CR37","doi-asserted-by":"publisher","first-page":"15217","DOI":"10.1002\/cam4.6209","volume":"12","author":"Z Zhang","year":"2023","unstructured":"Zhang Z, Wang D, Yang L, Zhao L, Yang L, Zhang J, et al. Efficacy and safety analysis of chemotherapy combined with immunotherapy compared with standard chemotherapy for advanced biliary tract malignant tumors. Cancer Med. 2023;12(14):15217\u201328.","journal-title":"Cancer Med"},{"key":"3877_CR38","doi-asserted-by":"publisher","first-page":"175628482211176","DOI":"10.1177\/17562848221117638","volume":"15","author":"H Kim","year":"2022","unstructured":"Kim H, Kim R, Jo H, Kim HR, Hong J, Ha SY, et al. Expression of PD-L1 as a predictive marker of sensitivity to immune checkpoint inhibitors in patients with advanced biliary tract cancer. Therap Adv Gastroenterol. 2022;15:17562848221117638.","journal-title":"Therap Adv Gastroenterol"},{"key":"3877_CR39","doi-asserted-by":"publisher","first-page":"1493234","DOI":"10.3389\/fimmu.2025.1493234","volume":"16","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Guo J, Ren T, Ma J, Cao D. Efficacy and safety of immune checkpoint inhibitors in advanced biliary tract cancer: a real-world study. Front Immunol. 2025;16:1493234.","journal-title":"Front Immunol"},{"issue":"7","key":"3877_CR40","doi-asserted-by":"publisher","first-page":"567","DOI":"10.2217\/imt-2021-0257","volume":"14","author":"R Giorgione","year":"2022","unstructured":"Giorgione R, Risaliti M, Bartolini I, Rossi G, Pillozzi S, Muiesan P, et al. The emerging role of immunotherapy in biliary tract cancer: a review of new evidence and predictive biomarkers. Immunotherapy. 2022;14(7):567\u201376.","journal-title":"Immunotherapy"},{"key":"3877_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03011-7","author":"C Huang","year":"2025","unstructured":"Huang C, Qiu Z, Huang H, Xiao X, Du F, Ji J, et al. Alterations in genomic features and the tumour immune microenvironment predict immunotherapy outcomes in advanced biliary tract cancer patients. Br J Cancer. 2025. https:\/\/doi.org\/10.1038\/s41416-025-03011-7.","journal-title":"Br J Cancer"}],"container-title":["World Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03877-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12957-025-03877-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12957-025-03877-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T08:47:15Z","timestamp":1749545235000},"score":1,"resource":{"primary":{"URL":"https:\/\/wjso.biomedcentral.com\/articles\/10.1186\/s12957-025-03877-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3877"],"URL":"https:\/\/doi.org\/10.1186\/s12957-025-03877-0","relation":{},"ISSN":["1477-7819"],"issn-type":[{"value":"1477-7819","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"assertion":[{"value":"24 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Due to the nature of this study no ethical approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"228"}}